The antibodies are everywhere and rising. The disease is far rarer. And no one can fully explain the gap between them. That is the strange position of alpha-gal syndrome, the tick-borne allergy to red meat, at a moment when its geographic footprint is expanding on several continents and its case counts are climbing. Scientists understand the trigger: a sugar called galactose-alpha-1,3-galactose, present in the saliva of certain ticks and in the flesh of most mammals, that some people’s immune systems come to treat as an enemy. What they do not understand is why only a minority of the people carrying the antibodies ever become allergic, and why the allergy can appear months after a bite while others with the same exposure never react. The condition is rising faster than the science that would explain it.
The mechanism itself is well established. Alpha-gal is a sugar found in most mammals but not in humans, whose immune systems therefore do not treat it as self. When a tick that carries the sugar in its saliva bites a person, the sugar can pass into the bloodstream and provoke the production of immunoglobulin E antibodies against it. From then on, eating red meat or dairy, or using products containing mammalian derivatives such as gelatin, can trigger a reaction hours later: hives, stomach pain, vomiting, in the worst cases anaphylaxis. At least two deaths worldwide have been attributed to the allergy. The delayed onset, hours after a meal and sometimes months after the relevant tick bite, makes the link easy to miss, for patients and clinicians alike.
The scale of exposure is now measurable, and it is striking. In the United States, the Centers for Disease Control and Prevention identified more than 110,000 suspected cases between 2010 and 2022 and estimates that as many as 450,000 Americans may be affected, a figure that would make it one of the country’s more common food allergies. The relevant tick, the lone star tick, is expanding its range. In Australia, which has the highest rates in the world, more than 700 people per 100,000 in tick-prone regions have the allergy, and suspected cases have risen about 22 percent per year since 2020, driven by the Australian paralysis tick. In Denmark, sensitization more than doubled between 1990 and 2016. In Japan, 2 to 4 percent of the population, up to 4.9 million people, carry antibodies to alpha-gal.
Sensitization, however, is not allergy. A study published this year in the CDC’s Morbidity and Mortality Weekly Report tested residual blood donor samples collected in 2024 and 2025 from ten states and estimated that 24 percent of the population aged 16 and older in the five highest-prevalence states, Arkansas, Kentucky, Missouri, Tennessee, and Virginia, would test positive for alpha-gal antibodies. Yet only a small minority of seropositive people have the clinical syndrome. The same pattern appears in Japan’s sensitization numbers and in earlier work showing that many people with the antibodies eat meat without incident. The antibody, in other words, is common; the disease is the exception. What converts exposure into allergy, and why some people convert and others do not, is the field’s central unanswered question.
The ecological forces pushing the numbers up are clearer. Climate change is shifting tick habitats; in Australia, the paralysis tick’s range, once confined to a small area of New South Wales, has spread along the east coast into Queensland. Growing deer populations are enlarging the host pool: white-tailed deer carry the lone star tick in the United States, and roe deer carry the castor bean tick, the main European vector, in Denmark and elsewhere. More ticks, more bites, more antibodies. Thomas Platts-Mills, the University of Virginia immunologist who has studied the syndrome since its discovery and is himself among the diagnosed, has argued that the deer boom is feeding the expansion.
The clinical picture compounds the problem. Symptoms are nonspecific, delayed, and easily attributed to food poisoning. Diagnosis requires a specific antibody test that is not part of routine panels, and even then, a positive test alone is not enough, since sensitized people without symptoms vastly outnumber patients. A CDC survey of 1,500 primary care clinicians found that nearly half had never heard of the syndrome, and only 5 percent felt very confident diagnosing or managing it. There is no treatment and no cure; management means avoiding mammalian meat and products, and carrying epinephrine for accidental exposures. The CDC’s new seroprevalence data carries a warning of its own: because antibodies are so common, testing patients without compatible symptoms risks overdiagnosis, treating a quarter of a state’s population as allergic when the vast majority are not.
The allergy is thus an ecological disease wearing a molecular costume: a sugar that most mammals make and humans do not, carried into the blood by ticks that are multiplying as the climate warms and deer populations swell. The antibodies are the measurable footprint of that ecology, spreading ahead of the disease itself. The mystery of who among the millions of sensitized will develop the allergy, and why, is where the next decade of research will be spent. In the meantime, the gap between the antibody maps and the case counts is the best picture science has of a disease that is still defining itself.
References
Rachel Fieldhouse, Meat allergy is on the rise: what scientists want to know. Nature, 31 July 2026. DOI: 10.1038/d41586-026-02362-2.
US Centers for Disease Control and Prevention, About alpha-gal syndrome. CDC, accessed July 2026.
Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors. MMWR 75, No. 25 (2026).
US Centers for Disease Control and Prevention, Knowledge and Practices Among Primary Care Clinicians About Alpha-gal Syndrome. MMWR 72, 815-820 (2023).